Incorporation of FLT3 inhibitors with chemotherapy or haematopoietic stem cell transplantation has significantly improved the prognosis of FLT3-ITD-positive AML in recent years [4–6], but high incidence of leukaemia relapse remains a problem to be solved [2, 3]. This evidence concerns the gene FLT3 and acute myeloid leukemia.